Healthcare cost offsets associated with empagliflozin for the treatment of chronic kidney disease in Italy: a budget impact analysis
Abstract
Background: Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, was recently approved for reimbursement in patients with chronic kidney disease (CKD) in Italy. This budget impact analysis (BIA) aimed to evaluate the direct health-care costs of managing CKD in Italian clinical practice, before and after the introduction of empagliflozin as an add-on to the current standard of care.
Methods: The budget impact analysis was conducted using a prevalence model based on a static cost calculator approach. The analysis population included adults eligible to receive add-on empagliflozin for CKD in Italy. Costs considered were those associated with treatment acquisition, CKD management, hospitalizations, and progression to kidney failure (KF). The model adopted the perspective of the Italian National Health Service (NHS) and a 3-year time horizon.
Results: Introducing add-on empagliflozin for CKD in Italy was estimated to reduce direct health-care costs by 4.7% and generate a total cost saving of €10.09 million over 3 years (total health-care costs of €216.07 million in a current scenario without empagliflozin vs €205.98 million in the future scenario with empagliflozin). Cost savings were driven by an increase in the number of patients who may be treated with SGLT2 inhibitors due to EMPA-KIDNEY clinical trial evidence for patients with urinary albumin-to-creatinine ratio <200 mg/g, and thereby reducing the number of those progressing to KF. Deterministic sensitivity…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.